NasdaqGM:PAHC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. More Details


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has Phibro Animal Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PAHC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.3%

PAHC

-1.1%

US Pharmaceuticals

-0.4%

US Market


1 Year Return

-19.0%

PAHC

10.8%

US Pharmaceuticals

18.3%

US Market

Return vs Industry: PAHC underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.

Return vs Market: PAHC underperformed the US Market which returned 18.3% over the past year.


Shareholder returns

PAHCIndustryMarket
7 Day0.3%-1.1%-0.4%
30 Day2.5%1.2%6.6%
90 Day-23.0%0.3%8.6%
1 Year-17.3%-19.0%13.7%10.8%21.0%18.3%
3 Year-48.9%-51.3%25.5%16.2%42.1%32.7%
5 Year-40.9%-45.2%39.6%23.3%85.6%64.7%

Price Volatility Vs. Market

How volatile is Phibro Animal Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Phibro Animal Health undervalued compared to its fair value and its price relative to the market?

41.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PAHC ($18.28) is trading below our estimate of fair value ($31.25)

Significantly Below Fair Value: PAHC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PAHC is good value based on its PE Ratio (22x) compared to the US Pharmaceuticals industry average (22.5x).

PE vs Market: PAHC is poor value based on its PE Ratio (22x) compared to the US market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: PAHC is poor value based on its PEG Ratio (1.2x)


Price to Book Ratio

PB vs Industry: PAHC is overvalued based on its PB Ratio (3.9x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Phibro Animal Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

17.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAHC's forecast earnings growth (17.8% per year) is above the savings rate (2.2%).

Earnings vs Market: PAHC's earnings (17.8% per year) are forecast to grow slower than the US market (22.1% per year).

High Growth Earnings: PAHC's earnings are forecast to grow, but not significantly.

Revenue vs Market: PAHC's revenue (2.2% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: PAHC's revenue (2.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PAHC's Return on Equity is forecast to be high in 3 years time (27.1%)


Next Steps

Past Performance

How has Phibro Animal Health performed over the past 5 years?

-10.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PAHC has high quality earnings.

Growing Profit Margin: PAHC's current net profit margins (4.2%) are lower than last year (6.6%).


Past Earnings Growth Analysis

Earnings Trend: PAHC's earnings have declined by 10.2% per year over the past 5 years.

Accelerating Growth: PAHC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PAHC had negative earnings growth (-38.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.6%).


Return on Equity

High ROE: PAHC's Return on Equity (17.8%) is considered low.


Next Steps

  • Explore strong past performing companies in the Pharmaceuticals & Biotech industry.

Financial Health

How is Phibro Animal Health's financial position?


Financial Position Analysis

Short Term Liabilities: PAHC's short term assets ($451.8M) exceed its short term liabilities ($157.2M).

Long Term Liabilities: PAHC's short term assets ($451.8M) exceed its long term liabilities ($438.7M).


Debt to Equity History and Analysis

Debt Level: PAHC's debt to equity ratio (210.8%) is considered high.

Reducing Debt: PAHC's debt to equity ratio has reduced from 983.5% to 210.8% over the past 5 years.

Debt Coverage: PAHC's debt is not well covered by operating cash flow (15%).

Interest Coverage: PAHC's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Phibro Animal Health current dividend yield, its reliability and sustainability?

2.63%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PAHC's dividend (2.63%) is higher than the bottom 25% of dividend payers in the US market (1.63%).

High Dividend: PAHC's dividend (2.63%) is low compared to the top 25% of dividend payers in the US market (4.56%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PAHC has been paying a dividend for less than 10 years.

Growing Dividend: PAHC's dividend payments have increased, but the company has only paid a dividend for 6 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (57.9%), PAHC's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PAHC's dividends in 3 years are forecast to be covered by earnings (54.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Jack Bendheim (73 yo)

6.58yrs

Tenure

US$3,023,918

Compensation

Mr. Jack Clifford Bendheim has been the President and Chief Executive Officer of Phibro Animal Health Corporation since 1988 and March 2014, respectively and serves as its Chairman. Mr. Bendheim served as ...


CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD3.02M) is about average for companies of similar size in the US market ($USD2.94M).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jack Bendheim
Chairman6.58yrsUS$3.02m50%
$ 369.7m
Richard Johnson
Chief Financial Officer18.08yrsUS$6.29mno data
Larry Miller
Chief Operating Officer4.25yrsUS$806.16kno data
Daniel Bendheim
Executive VP of Corporate Strategy & Director6.92yrsUS$644.33kno data
Rob Aukerman
President of North America Region1.42yrsUS$605.88kno data
Thomas Dagger
Senior VP13.92yrsUS$564.07kno data
Lisa Escudero
Senior Vice President of Human Resources3.58yrsno datano data
Dean Warras
Senior Vice President of Strategic Alliances4.25yrsUS$832.24kno data
Jonathan Bendheim
President of MACIE Region2.17yrsno datano data
George Moffett
Managing Director of Ferro Metal & Chemical Corporation Ltdno datano datano data
Ramon Fuenmayor
President South America Region3.33yrsno datano data
Jean Filippi
President of Asia Pacific Region0.75yrno datano data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: PAHC's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jack Bendheim
Chairman6.58yrsUS$3.02m50%
$ 369.7m
Daniel Bendheim
Executive VP of Corporate Strategy & Director6.92yrsUS$644.33kno data
Jonathan Bendheim
President of MACIE Region2.17yrsno datano data
Samuel Gejdenson
Independent Non-Executive Director16.75yrsUS$60.00kno data
Mary Malanoski
Independent Non Executive Director16.42yrsUS$40.00kno data
Carol Wrenn
Independent Director10.25yrsUS$60.00k0.0025%
$ 18.3k
E. Corcoran
Independent Non-Executive Director12.42yrsUS$50.00k0.049%
$ 365.6k
Gerald Carlson
Independent Director12.75yrsUS$40.00kno data

12.4yrs

Average Tenure

67.5yo

Average Age

Experienced Board: PAHC's board of directors are seasoned and experienced ( 12.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Phibro Animal Health Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Phibro Animal Health Corporation
  • Ticker: PAHC
  • Exchange: NasdaqGM
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$739.492m
  • Shares outstanding: 40.45m
  • Website: https://www.pahc.com

Number of Employees


Location

  • Phibro Animal Health Corporation
  • Glenpointe Centre East
  • 3rd Floor
  • Teaneck
  • New Jersey
  • 07666-6712
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PAHCNasdaqGM (Nasdaq Global Market)YesClass A Common StockUSUSDApr 2014
PB8DB (Deutsche Boerse AG)YesClass A Common StockDEEURApr 2014

Biography

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segment ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 00:01
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.